Monoclonal antibodies Archives

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally […]

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials […]

December 15, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Solve Therapeutics launches to tackle cancer

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company’s formation reunites the former VelosBio Inc. team. SolveTx is fully operational with more than 25 employees and is actively pursuing discovery and development efforts at its 10,000-square-foot laboratory in San Diego. Solve […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Antibody discovery could lead to new therapies to tackle Strep A

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads to an effective immune response against bacteria. The researchers say the discovery could explain why so many group A strep vaccines have failed. The results […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Touchlight receives new grant to further develop doggybone DNA vaccine platform

UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone DNA vaccine platform. The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralizing antibodies and durable T […]

November 29, 2022 - 2 minutesmins - By Liza Laws

cardiology cardiovascular disease heart attack

News and Trends 23 Nov 2022

Trial to start for new heart attack drug

A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients has been given to the first subjects in a trial run by Infex Therapeutics. Infex Therapeutics is an anti-infectives company and announced the first subjects were dosed in the phase 1 study in healthy volunteers evaluating the company’s lead […]

November 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Nov 2022

CatalYm raises €50M to boost solid tumors trial

CatalYm has announced the close of a €50 million ($49 million) series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. The financing will support the clinical development of its […]

November 22, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

Sanofi’s treatment, Enjaymo, for hemolytic anemia in adult patients with cold agglutinin disease (CAD), has been granted marketing authorization by the European Commission (EC). Enjaymo is the first and only approved therapeutic option for the rare, serious and chronic autoimmune disease where the body mistakenly attacks healthy red blood cells and causes their rupture, known […]

November 18, 2022 - 4 minutesmins - By Liza Laws

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

November 14, 2022 - 9 minutesmins - By Jim Cornall

News and Trends 11 Nov 2022

Prurigo nodularis treatment recommended for EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron. The European Commission is expected […]

November 11, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Monoclonal antibodies

Astellas gastric cancer drug meets phase 3 primary endpoint

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

Solve Therapeutics launches to tackle cancer

Antibody discovery could lead to new therapies to tackle Strep A

Touchlight receives new grant to further develop doggybone DNA vaccine platform

Trial to start for new heart attack drug

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

CatalYm raises €50M to boost solid tumors trial

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Prurigo nodularis treatment recommended for EU approval

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!